Brufau-Cochs et al., in a review in 2024, showed that sphingosine-1-phosphate receptor modulators such as fingolimod are associated with a higher risk of basal cell carcinoma but not squamous cell carcinoma or melanoma [14]. Here, S1PR1 is linked to basal cell carcinoma.